Happe, Svenja

[["dc.bibliographiccitation.firstpage","230"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","237"],["dc.bibliographiccitation.volume","257"],["dc.contributor.author","Hoegl, Birgit"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Ferini-Strambi, Luigi"],["dc.contributor.author","Hadjigeorgiou, Georgios M."],["dc.contributor.author","Hornyak, Magdolna"],["dc.contributor.author","de Weerd, A. L."],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Stiasny-Kolster, Karin"],["dc.contributor.author","Gschliesser, Viola"],["dc.contributor.author","Egatz, Renata"],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Hening, Wayne A."],["dc.contributor.author","Allen, Richard P."],["dc.date.accessioned","2018-11-07T08:46:22Z"],["dc.date.available","2018-11-07T08:46:22Z"],["dc.date.issued","2010"],["dc.description.abstract","The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment. This prospective, open-label 6-month study was conducted in six European countries and included 65 patients (85% treatment naive) with idiopathic RLS. Levodopa was flexibly up-titrated to a maximum dose of 600 mg/day. Presence of augmentation was diagnosed independently by two international experts using established criteria. In addition to the augmentation severity rating scale (ASRS), changes in RLS severity (International RLS severity rating scale (IRLS), clinical global impression (CGI)) were analyzed. Sixty patients provided evaluable data, 35 completed the trial and 25 dropped out. Augmentation occurred in 60% (36/60) of patients, causing 11.7% (7/60) to drop out. Median time to occurrence of augmentation was 71 days. The mean maximum dose of levodopa was 311 mg/day (SD: 105). Patients with augmentation compared to those without were significantly more likely to be on higher doses of levodopa (a parts per thousand yen300 mg, 83 vs. 54%, P = 0.03) and to show less improvement of symptom severity (IRLS, P = 0.039). Augmentation was common with levodopa, but could be tolerated by most patients during this 6-month trial. Patients should be followed over longer periods to determine if dropout rates increase with time."],["dc.description.sponsorship","Pharmacia (now Pfizer) USA"],["dc.identifier.doi","10.1007/s00415-009-5299-8"],["dc.identifier.isi","000274251700011"],["dc.identifier.pmid","19756826"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6747"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20677"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0340-5354"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","73"],["dc.bibliographiccitation.journal","Health and Quality of Life Outcomes"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Scholz, Hanna"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Happe, Svenja"],["dc.contributor.author","Bengel, Juergen"],["dc.contributor.author","Kohnen, Ralf"],["dc.contributor.author","Hornyak, Magdolna"],["dc.date.accessioned","2018-11-07T08:51:41Z"],["dc.date.available","2018-11-07T08:51:41Z"],["dc.date.issued","2011"],["dc.description.abstract","Background: Restless legs syndrome (RLS) is a chronic disorder with substantial impact on quality of life similar to that seen in diabetes mellitus or osteoarthritis. Little is known about the psychological characteristics of RLS patients although psychological factors may contribute to unfavourable treatment outcome. Methods: In an observational cross-sectional design, we evaluated the psychological features of 166 consecutive RLS patients from three outpatient clinics, by means of the Symptom Checklist 90-R (SCL-90-R) questionnaire. Additionally, the Beck Depression Inventory-II (BDI-II) and the International RLS Severity Scale (IRLS) were measured. Both treated and untreated patients were included, all patients sought treatment. Results: Untreated patients (n = 69) had elevated but normal scores on the SCL-90-R Global Severity Index (GSI; p = 0.002) and on the sub-scales somatisation (p < 0.001), compulsivity (p = 0.003), depression (p = 0.02), and anxiety (p = 0.004) compared with a German representative sample. In the treated group, particularly in those patients who were dissatisfied with their actual treatment (n = 62), psychological distress was higher than in the untreated group with elevated scores for the GSI (p = 0.03) and the sub-scales compulsivity (p = 0.006), depression (p = 0.012), anxiety (p = 0.031), hostility (p = 0.013), phobic anxiety (p = 0.024), and paranoid ideation (p = 0.012). Augmentation, the most serious side effect of dopaminergic, i.e. first-line treatment of RLS, and loss of efficacy were accompanied with the highest psychological distress, as seen particularly in the normative values of the sub-scales compulsivity and anxiety. Generally, higher RLS severity was correlated with higher psychological impairment (p < 0.001). Conclusion: Severely affected RLS patients show psychological impairment in multiple psychological domains which has to be taken into account in the treatment regimen."],["dc.identifier.doi","10.1186/1477-7525-9-73"],["dc.identifier.isi","000295806600001"],["dc.identifier.pmid","21933380"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6985"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21994"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7525"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]